Hair loss, or alopecia, is often associated with cancer therapies and, in particular, with cytotoxic chemotherapy. While this side effect is most often temporary –…
Due to recent advances in cancer treatment, especially in the field of immunotherapy, chemotherapy treatment options for mesothelioma have taken a back seat. However, this…
This article aims to build on the Part 1 of this series. Out of necessity, mesothelioma patients more than other patient groups are savvy consumers…
UPDATE: Deadline extended to November 17 at 11:59 PM ET. Thanks to the generous support of our patients, families, caregivers, corporate supporters, and the many…
The Mesothelioma Applied Research Foundation announced the recipients of its most recent research grants cycle awards totaling $400,000. This brings the total mesothelioma research funded…
The American Society for Clinical Oncology’s (ASCO) annual meeting concluded last week in Chicago, IL. As the largest oncology meeting in the world, ASCO is…
Watch the video of Dr. Pingpank as he discusses mesothelioma surgery and treatment at UMPC. We meet today with Dr. James Pingpank of the Hillman…
The Peer Reviewed Cancer Research Program (PRCRP) is soliciting input regarding the Quality of Life (QoL) and psychosocial aspects of cancer care (diagnosis/treatment/transition to survivorship…
Mesothelioma in and of itself is a misunderstood diagnosis. As a cancer that affects roughly 3,000 Americans per year, it is often mistakenly thought of…
Last week, the Polaris Group announced positive results of its Phase 2/3 clinical trial evaluating the effectiveness of an arginine degrading enzyme agent called ADI-PEG 20.…